Estey EH - Search Results

1

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Schimmer AD, et al. Among authors: estey eh. J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652057 Free PMC article. Clinical Trial.

2

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Gandhi V, et al. Among authors: estey eh. J Clin Oncol. 2002 Feb 1;20(3):665-73. doi: 10.1200/JCO.2002.20.3.665. J Clin Oncol. 2002. PMID: 11821446 Clinical Trial.

3

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.

Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Lin CW, et al. Leuk Res. 2002 Jun;26(6):551-9. doi: 10.1016/s0145-2126(01)00170-9. Leuk Res. 2002. PMID: 12007503

4

The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.

Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. Konopleva M, et al. Br J Haematol. 2002 Aug;118(2):521-34. doi: 10.1046/j.1365-2141.2002.03637.x. Br J Haematol. 2002. PMID: 12139741 Free article.

5

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.

Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Alvarado Y, et al. Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90. doi: 10.1007/s00280-002-0546-z. Epub 2002 Nov 13. Cancer Chemother Pharmacol. 2003. PMID: 12497211

6

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.

Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. Cortes J, et al. Cancer. 2003 Mar 1;97(5):1234-41. doi: 10.1002/cncr.11180. Cancer. 2003. PMID: 12599230 Free article. Clinical Trial.

7

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Giles FJ, et al. Among authors: estey eh. J Clin Oncol. 2003 Mar 15;21(6):1050-6. doi: 10.1200/JCO.2003.04.023. J Clin Oncol. 2003. PMID: 12637470 Clinical Trial.

8

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Giles FJ, et al. Among authors: estey eh. J Clin Oncol. 2003 May 1;21(9):1722-7. doi: 10.1200/JCO.2003.11.016. J Clin Oncol. 2003. PMID: 12721247 Clinical Trial.

9

Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.

Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Konopleva M, et al. Among authors: estey eh. Haematologica. 2003 Jul;88(7):733-6. Haematologica. 2003. PMID: 12857550 Clinical Trial.

10

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Cheson BD, et al. Among authors: estey eh. J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036. J Clin Oncol. 2003. PMID: 14673054

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters